×

Biotech and Pharmaceuticals Pharmaceuticals

  • Your Health, Your Dollars - A CNBC Special Report

    Critics of the Affordable Care Act say they are not seeing any change in costs and are worried that government-run health care will increase taxes and allow insurance companies to operate without rules.

  • Sphygmomanometer

    Many consumers assume that their health insurer, hospital, or state medical licensing agencies have vetted physicians who are open for business, but oversight is more lax than you might think.

  • pill_bottle_forms_200.jpg

    What used to be mostly a matter of phony billing has spread to questionable medical procedures and identity theft, costing patients and insurers more than ever.

  • doctor_computer_200.jpg

    Though the U.S. had made much progress taking medical record keeping into the digital age, there's still some doubt that the government will reach its target by the prescribed deadline.

  • cash_pile_93.jpg

    The reasons  Americans pay more than other industrialized countries for similar health care come down to how the system is run, starting with the bottom line.

  • stethoscope_money_200.jpg

    Like many things in America these days, health care has been politicized. While the policy debate may strike many in Washington as all-important, for the majority of average Americans health care is primarily a matter of goods and services

  • office_worker_phone_200.jpg

    With so many Americans working as consultants or freelancers because of the bad economy, more people are paying for their own coverage. Here's a guide to finding a provider.

  • Mylan's Bresch on Jobs

    Heather Bresch, Mylan CEO, discusses the difference between government and private sector jobs, and her company's current job situation.

  • There's a lot going on in this volatile market, but Cramer thinks it's important to monitor the following things in particular.

  • Here's a day-by-day look at the earnings reports, economic data and political events Cramer plans to monitor.

  • Even in this difficult market, the "Mad Money" host thinks play could be profitable.

  • Cramer makes the call on viewers' favorite stocks.

  • Sigmund Freud

    One out of 4 Americans will have either a substance abuse or addiction problem at some point in their lives. Some of these addicts have even managed to change the world. Take for example, Sigmund Freud. Now the author of a new book takes us on an amazing journey looking at the "Anatomy of Addiction."

  • Carl Icahn

    Forest Laboratories said it won backing from proxy advisory firm ISS for all 10 of its board nominees in a proxy battle with billionaire investor Carl Icahn.

  • Cramer makes the call on viewers' favorite stocks.

  • Herb on the Street: Dendreon

    CNBC's Herb Greenberg reports the biotech company missed sales guidance in a big way.

  • Alkermes' CEO Richard Pops tells Cramer why the company is successful, and where it is going.

  • Sales at Bayer, the German pharmaceuticals company, rose 5.4 percent to 9,252 million euro ($13,282 million) in the second quarter.

  • In the next 14 months, patents for the top 20 drugs in the U.S. are set to expire. Although makers of such top-selling drugs, such as Lipitor and Plavix, will no longer have a monopoly on these drug formulas, pharmaceutical stocks will be able to weather the loss of these patents, said two health-care analysts.

  • pharma_new2.jpg

    The chief executive and founder of Actelion, one of the world's biggest biotechnology companies, said the firm would stay independent despite pressure from activist shareholders.